MedTrace Logo

A Study of SHR-1918 In Participants With Hypertriglyceridemia

NCT07349615 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2026-02-09

No results posted yet for this study

Summary

The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypertriglyceridemia. The efficacy and safety of SHR-1918 will be evaluated after 24-weeks and 48-weeks treatment.

Conditions

  • Hypertriglyceridemia

Interventions

DRUG

SHR-1918/ SHR-1918 placebo

SHR-1918/ SHR-1918 placebo Dose 1

DRUG

SHR-1918/ SHR-1918 placebo

SHR-1918/ SHR-1918 placebo Dose 2

Sponsors & Collaborators

  • Beijing Suncadia Pharmaceuticals Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-28
Primary Completion
2027-11-30
Completion
2027-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07349615 on ClinicalTrials.gov